Dr. Rossi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Mount Sinai School Of Medicine Of New York University One Gustav
1 Gustave L Levy Pl
New York, NY 10029
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2010 - 2013
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Internal Medicine, 2007 - 2010
George Washington University School of Medicine and Health SciencesClass of 2007
Certifications & Licensure
FL State Medical License 2022 - Present
NY State Medical License 2010 - 2025
PA State Medical License 2007 - 2010
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
Clinical Trials
- BiRd vs. Rd as Initial Therapy in Multiple Myeloma Start of enrollment: 2016 Feb 01
- Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M) Start of enrollment: 2018 Oct 23
- Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma Start of enrollment: 2012 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes.Santiago Thibaud, Ryan L Subaran, Scott Newman, Alessandro Lagana, David T Melnekoff
Blood Cancer Discovery. 2024-11-01 - 1 citationsAbsolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma.Mateo Mejia Saldarriaga, Darren Pan, Caitlin Unkenholz, Tarek H Mouhieddine, Juan Esteban Velez-Hernandez
Blood Advances. 2024-08-13 - 1 citationsImpact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel.Saurabh Zanwar, Surbhi Sidana, Leyla Shune, Omar Castaneda Puglianini, Oren Pasvolsky
Journal of Hematology & Oncology. 2024-06-06
Press Mentions
First Patient Dosed with Off-the-Shelf UCARTCS1 Product Candidate for Relapsed/Refractory Multiple MyelomaNovember 20th, 2019
Treating Multiple Myeloma: Common Side Effects to Watch Out ForJuly 1st, 2019- Treating Multiple Myeloma: Questions to Ask Your DoctorJune 26th, 2019
- Join now to see all
Professional Memberships
- Member
- Member
- International Kidney and Monoclonal Gammopathy Research GroupMember
- International Myeloma SocietyMember
Other Languages
- Portuguese, Spanish, French, Italian
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
